Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.45 |
| ▸ | HINT1 | P49773 | 1/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | KRAS | P01116 | 5/20 | 0.43 |
| ▸ | PNP | P00491 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20017120 | 0.91 | ADORA3 (0.46) | ADORA3STING1HINT1NT5EPDE3B | |
| SCHEMBL19590338 | 0.90 | HINT1 (0.49) | ADORA3STING1HINT1NT5EPDE3B | |
| SCHEMBL19590344 | 0.86 | NT5E (0.43) | ADORA3STING1HINT1NT5EPDE3B | |
| SCHEMBL21385572 | 0.85 | STING1 (0.48) | ADORA3STING1HINT1NT5EPDE3B | |
| SCHEMBL19590288 | 0.82 | KRAS (0.48) | STING1NT5EKRASPNP | |
| SCHEMBL20879526 | 0.82 | STING1 (0.45) | ADORA3STING1HINT1NT5EPDE3B | |
| SCHEMBL21385655 | 0.81 | HINT1 (0.49) | ADORA3STING1HINT1NT5EPDE3B | |
| SCHEMBL20879497 | 0.81 | STING1 (0.45) | ADORA3STING1HINT1NT5EPDE3B | |
| SCHEMBL23519970 | 0.79 | ADORA3 (0.48) | ADORA3 | |
| SCHEMBL19590216 | 0.79 | ADORA3 (0.48) | ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10464965-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10421771-B2 | — | — | 2019-09-24 | — | — | US | disclosed |
| US-10420788-B2 | — | — | 2019-09-24 | — | — | US | disclosed |
| EP-3466959-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen BioPharma, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| US-9815864-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464965-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NT5C3B, ADAR | ADORA3 59/4885STING1 301/4885HINT1 137/4885 |
| US-10420788-B2 | — | PNP, ADAR, NT5C2 | ADORA3 61/4885STING1 284/4885HINT1 126/4885 |
| US-10421771-B2 | — | PNP, ADAR, NT5C2 | ADORA3 61/4885STING1 284/4885HINT1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.